CNR1 and melanoma: Previous studies have demonstrated that the activation of CB1 and CB2 by external plant-derived compounds results in the inhibition of early tumour growth in various malignancies, including non-small cell lung carcinoma [30], prostate cancer [31], and melanoma [32], where these receptors function as mediators that stimulate diverse molecular signalling pathways [26].